Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies
Conditions
Interventions
AMXT 1501 Dicaprate
DFMO
+3 more
Locations
8
United States
START Los Angeles
Los Angeles, California, United States
START Cancer Research New York-Long Island
Lake Success, New York, United States
University of Texas-MD Anderson
Houston, Texas, United States
Lumi Research
Houston, Texas, United States
Laguna Clinical Research Associates
Laredo, Texas, United States
START Mountain Region
West Valley City, Utah, United States
Start Date
January 26, 2026
Primary Completion Date
February 28, 2028
Completion Date
December 29, 2028
Last Updated
March 12, 2026
NCT06545682
NCT06605443
NCT07429123
NCT07428941
NCT07341737
NCT03057327
Lead Sponsor
Aminex Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions